Marker Therapeutics, Inc.

Category: Media Coverage

Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.

US Department of Defense Funds Phase 2 Trial of TapImmune Breast Cancer Vaccine

The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $3.7 million to conduct a Phase 2 trial of TapImmune’s HER21-targeted T-cell vaccine in women with the breast cancer known as ductal carcinoma in situ (DCIS).

Read More

Doctor developing vaccine that would prevent breast, ovarian and certain lung cancers

A Jacksonville doctor is working on a vaccine that would fight off several types of cancer. He said he’s about halfway through the process before it would get to the market. A vaccine called TPIV 200 would prevent breast, ovarian and some lung cancers, and it is being created in a Mayo Clinic lab by Dr. Keith Knutson.

Read More

Jacksonville doctor developing vaccine that would prevent breast, ovarian and certain lung cancers

A Jacksonville doctor is working on a vaccine that would fight off several types of cancer. He said he’s about halfway through the process before it would get to the market. “If it works, that would be a good thing for all us women,” Jacksonville resident Lakysha Tyler said.

Read More

Cancer vaccine in the works by Jacksonville doctor

A professor in Jacksonville said he’s closer to his dream of a vaccine to prevent breast, ovarian and some types of lung cancer. According to a FOX 13 report, immunology professor Dr. Keith Knutson said his dream would be to develop a vaccine to prevent cancer development.

Read More

Vaccine could prevent breast, ovarian, lung cancer

It’s a dream many parents would welcome for their children: a vaccine that could prevent breast, ovarian and some lung cancers. It’s also the dream of immunology professor Dr. Keith Knutson. “The hope is we can develop vaccines before the development of cancer much in the way that we use a polio vaccine or a flu vaccine,” Dr. Knutson tells us in in his Mayo Clinic Jacksonville laboratory.

Read More

T.L. Williams; TapImmune; 1904 Music Hall

Monday on First Coast Connect we spoke with former CIA operative and author T. L. Williams about his new novel and Chinese cyber hacking. We also heard from TapImmune CEO Glynn Wilson about a breast cancer study at the Mayo Clinic. WJCT’s Indie Endeavor host Ryan Benk and 1904 Music Hall co-owner Jason Hunnicut announced a new partnership at the downtown venue.

Read More

TapImmune improves T-cell vaccine formulation ahead of Ph II trials

If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.

Read More

Exclusive: Interview With TapImmune, Inc. (NASDAQ: TPIV) President And COO, Dr. John Bonfiglio

If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.

Read More